الفهرس 
Introduction
FCAT liver terminologyOnly 14 pages are availabe for public view
 |  | from | 16 |  |  |
| | | from | 16 | | |
Abstract
HCC is a condition in which patients usually present beyond potentially curative options. In this scenario, systemic agents and LRTs have an established palliative role. Although extending patient survival is the ultimate therapeutic goal, showing this benefit has been difficult in HCC. In a disease commonly managed by multiple different therapies (resection, transplantation, ablation, LRT, systemic) with routine cross-over between treatments, identifying a survival benefit attributable to one therapy without prohibitively large studies becomes difficult. This scenario is clinically significant and unique to HCC, in which survival is dependent on both the cancer and functional status of the cirrhotic liver (competing risks of death). (Lewandowski RJ et al., 2010). The underlying liver disease and its associated mortality are intertwined intricately with the treatment of HCC and can impact the end point of survival. The aim of this study was to investigate whether tumor response could be used as a prognosticator of survival. If so, one could design future randomized controlled trials validating radiographic response as a surrogate of survival. (Salem R et al., 2011).